Investors Buy Large Volume of Day One Biopharmaceuticals Call Options (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) was the recipient of unusually large options trading activity on Friday. Investors acquired 20,759 call options on the stock. This is an increase of approximately 519% compared to the typical volume of 3,354 call options.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Lauren Merendino sold 5,814 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $67,442.40. Following the completion of the sale, the insider directly owned 60,157 shares in the company, valued at $697,821.20. This trade represents a 8.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Vasconcelles sold 2,728 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the completion of the transaction, the insider owned 4,397 shares of the company’s stock, valued at approximately $51,005.20. This represents a 38.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,461 shares of company stock valued at $422,948 over the last quarter. 6.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DAWN. Rubric Capital Management LP bought a new position in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $23,808,000. Vestal Point Capital LP raised its stake in Day One Biopharmaceuticals by 94.4% during the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after purchasing an additional 2,525,000 shares during the period. AIGH Capital Management LLC acquired a new position in shares of Day One Biopharmaceuticals in the third quarter worth $10,719,000. Mak Capital One LLC bought a new position in Day One Biopharmaceuticals during the third quarter valued at approximately $10,212,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at $9,758,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals News Summary

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

Analyst Upgrades and Downgrades

DAWN has been the subject of several research reports. Needham & Company LLC reiterated a “hold” rating on shares of Day One Biopharmaceuticals in a research report on Friday. TD Cowen cut Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. JonesTrading reissued a “hold” rating and set a $21.50 target price (up from $20.00) on shares of Day One Biopharmaceuticals in a research note on Friday. Wedbush lifted their target price on Day One Biopharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Finally, Zacks Research lowered Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $25.56.

Day One Biopharmaceuticals Stock Up 65.9%

Shares of NASDAQ:DAWN opened at $21.20 on Friday. The firm’s 50-day simple moving average is $11.10 and its 200-day simple moving average is $9.05. Day One Biopharmaceuticals has a fifty-two week low of $5.64 and a fifty-two week high of $21.23. The company has a market cap of $2.19 billion, a price-to-earnings ratio of -20.58 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The company had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. On average, research analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.